StockDrifts LogoStockDrifts

Opaleye Management 13F Portfolio

Portfolio Manager
Opaleye Management INC
Performance
+40.13% (2026 Q2)
AUM (13F)
$1.10B
# of Holdings
58
Performance Rank
Allocation (Top 20)
82.41%
Latest filing
Q2 2026

Opaleye Management INC Holdings Map

Top 50 Opaleye Management INC Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
LQDA
LIQUIDIA CORPORATION
17.67%2.45M$195.1M
-3.83%(-97.50K)
2025-Q2: 2.48M shares2025-Q3: 2.62M shares2025-Q4: 2.44M shares2026-Q1: 2.54M shares2026-Q2: 2.45M shares
$12.49(+522.31%)
2026-06-30
ETON
ETON PHARMACEUTICALS INC
9.38%2.86M$103.5M
+0.00%(+0)
2025-Q2: 2.86M shares2025-Q3: 2.86M shares2025-Q4: 2.86M shares2026-Q1: 2.86M shares2026-Q2: 2.86M shares
$5.78(+918.63%)
2026-06-30
HROW
HARROW INC
9.23%2.40M$101.9M
-15.26%(-432.23K)
2025-Q2: 3.90M shares2025-Q3: 3.90M shares2025-Q4: 3.90M shares2026-Q1: 2.83M shares2026-Q2: 2.40M shares
$6.49(+516.70%)
2026-06-30
IRON
DISC MEDICINE INC
5.66%855.0K$62.5M
+103.09%(+434.00K)
2025-Q2: 186.4K shares2025-Q3: 193.8K shares2025-Q4: 200.0K shares2026-Q1: 421.0K shares2026-Q2: 855.0K shares
$65.42(+20.51%)
2026-06-30
URGN
UROGEN PHARMA LTD
4.8%1.44M$53.0M
+0.70%(+10.00K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 268.4K shares2026-Q1: 1.43M shares2026-Q2: 1.44M shares
$19.31(+150.56%)
2026-06-30
APGE
APOGEE THERAPEUTICS INC
4.69%390.0K$51.8M
+0.00%(+0)
2025-Q2: 0 shares2025-Q3: 363.3K shares2025-Q4: 388.3K shares2026-Q1: 390.0K shares2026-Q2: 390.0K shares
$42.78(+214.53%)
2026-06-30
MGTX
MEIRAGTX HLDGS PLC
4.34%3.55M$48.0M
+67.20%(+1.43M)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 390.8K shares2026-Q1: 2.12M shares2026-Q2: 3.55M shares
$9.28(+45.63%)
2026-06-30
SLGL
SOL-GEL TECHNOLOGIES LTD
3.36%500.0K$37.1M
+0.00%(+0)
2025-Q2: 0 shares2025-Q3: 204.8K shares2025-Q4: 453.7K shares2026-Q1: 500.0K shares2026-Q2: 500.0K shares
$30.85(+170.74%)
2026-06-30
RZLT
REZOLUTE INC
2.97%6.30M$32.8M
+0.00%(+0)
2025-Q2: 903.4K shares2025-Q3: 903.4K shares2025-Q4: 6.29M shares2026-Q1: 6.30M shares2026-Q2: 6.30M shares
$5.63(-18.22%)
2026-06-30
TGTX
TG THERAPEUTICS INC
2.66%535.0K$29.4M
+0.00%(+0)
2025-Q2: 535.0K shares2025-Q3: 535.0K shares2025-Q4: 535.0K shares2026-Q1: 535.0K shares2026-Q2: 535.0K shares
$16.03(+203.98%)
2026-06-30

About Opaleye Management INCโ€™s portfolio

Opaleye Management INC reports $1.10B in US-listed equity holdings across 58 positions in its most recent 13F filing. Its largest disclosed positions are LQDA (17.7%), ETON (9.4%) and HROW (9.2%). The top 20 holdings account for 82.41% of reported assets. Its disclosed equity book has returned +177.01% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.

Portfolio concentration

Portfolio concentration
LQDA โ€” 17.8% ($195.14M)ETON โ€” 9.4% ($103.53M)HROW โ€” 9.3% ($101.93M)IRON โ€” 5.7% ($62.53M)URGN โ€” 4.8% ($52.99M)APGE โ€” 4.7% ($51.76M)MGTX โ€” 4.4% ($47.96M)SLGL โ€” 3.4% ($37.07M)RZLT โ€” 3.0% ($32.76M)TGTX โ€” 2.7% ($29.39M)Other โ€” 34.8% ($382.35M)
65%in top 10
  • LQDA17.8%
  • ETON9.4%
  • HROW9.3%
  • IRON5.7%
  • URGN4.8%
  • APGE4.7%
  • MGTX4.4%
  • SLGL3.4%
  • RZLT3.0%
  • TGTX2.7%
  • Other34.8%

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

New buys
7
IMMXIMMIX BIOPHARMA INC2.2%
GLUEMONTE ROSA THERAPEUTICS INC1.6%
REPLREPLIMUNE GROUP INC1.4%
VSTMVERASTEM INC0.6%
+3 opened
Added to
15
IRONDISC MEDICINE INC+103.1%
MGTXMEIRAGTX HLDGS PLC+67.2%
CABACABALETTA BIO INC+180.0%
EDITEDITAS MEDICINE INC+100.4%
+11 more
Trimmed
12
HROWHARROW INC-15.3%
LQDALIQUIDIA CORPORATION-3.8%
SNWVSANUWAVE HEALTH INC-68.8%
JBIOJADE BIOSCIENCES INC-66.1%
+8 more

Unlock alerts, watchlists & AI chat

Sign up free to track Opaleye Management INC, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Opaleye Management INCโ€™s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1595855). View Opaleye Management INCโ€™s 13F filings on SEC

More 13F analyses

View all